Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinxieling is a Traditional Chinese Medicine (TCM) herbal formula developed and utilized by the Guangdong Provincial Hospital of Traditional Chinese Medicine for the treatment of psoriasis vulgaris. It is primarily indicated for patients exhibiting the blood-stasis or blood-heat syndromes according to TCM diagnostic criteria. The formula is composed of multiple herbal ingredients, including *Rehmannia glutinosa*, *Salvia miltiorrhiza*, and *Dictamnus dasycarpus*, which are thought to work synergistically to modulate the immune system, inhibit keratinocyte proliferation, and reduce systemic inflammation. Clinical research has focused on its ability to alter microRNA expression profiles and downregulate pro-inflammatory cytokines such as TNF-α, IL-17, and IL-23, which are central to the pathogenesis of psoriasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yinxieling.